
Dean Seal
Breaking Financial News Reporter at The Wall Street Journal
Breaking Financial News Reporter at Dow Jones Newswires
breaking financial news @wsj and @dowjones
Articles
-
2 days ago |
tradingview.com | Dean Seal
Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, DemandATDAlimentation Couche-Tard logged a lower profit in its fiscal fourth quarter as lower prices and demand for fuel in the U.S. ate into its revenue. The Canadian convenience-store chain posted a profit of $439.4 million, or 46 cents a share, for the quarter ended April 27. That's down slightly from $453 million, or 47 cents a share, in the comparable quarter a year earlier.
-
2 days ago |
tradingview.com | Dean Seal
Micron Technology 3Q Profit Soars as AI Boom Boosts SalesMUMicron Technology notched a big leap in sales and earnings for its latest completed quarter amid booming demand for artificial-intelligence-driven memory. The memory-chip maker posted a profit of $1.89 billion, or $1.68 a share, for the quarter ended May 29. That is up from $332 million, or 30 cents a share, in the comparable quarter a year earlier. Stripping out one-time items, adjusted earnings were $1.91 a share.
-
2 days ago |
wsj.com | Dean Seal
Global dealmaking in the first half of the year fell to a two-decade low as tariffs, high interest rates, a choppy market and uncertainty around the Trump administration’s policies stalled a rebound in M&A activity. The worldwide tally of mergers, acquisitions, divestitures, financings and joint ventures so far in 2025 was down 16% year-over-year at 16,663, its lowest level since 2005, according to financial data company Mergermarket. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.
-
4 days ago |
tradingview.com | Dean Seal
FTC Resolves Antitrust Probe Into Omnicom-Interpublic MergerIPGOMCThe Federal Trade Commission said it struck a deal with Omnicom Group and Interpublic Group that resolves its antitrust concerns with their proposed $13.5 billion merger.
-
1 week ago |
tradingview.com | Dean Seal
Incyte Says FDA Extended Review Period for OpzeluraINCYIncyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11. The biopharmaceutical company said Friday that the U.S. Food and Drug Administration has extended the review period by three months to Sept.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 2K
- DMs Open
- No

RT @sabelaojeaguix: I spoke to the @WSJ team about what went wrong with Rent the Runway. Special thanks to @eadean1418. Go check out the vi…

RT @WSJCFO: Hertz Hires Finance Chief from Spirit Airlines https://t.co/AOlsmHPu4L via @WSJ @JDeanSeal

RT @ukpapers: 🇺🇸 ConocoPhillips To Buy Marathon Oil ▫The $17.1 billion deal marks the latest major consolidation in the energy sector ▫@JD…